We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current APLS market cap is 3.34B. The company's latest EPS is USD -4.3167 and P/E is -6.39.
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Total Revenue | 94.97M | 110.4M | 146.38M | 172.33M | 199.68M |
Operating Income | -120.44M | -137.08M | -84.52M | -62.09M | -29.44M |
Net Income | -122.04M | -140.24M | -85.58M | -66.42M | -37.66M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Total Revenue | 0 | 250.65M | 66.56M | 75.42M | 396.59M |
Operating Income | -288.02M | -213.73M | -536.28M | -594.61M | -517.12M |
Net Income | -304.71M | -344.87M | -746.35M | -652.17M | -525.63M |
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Total Assets | 915.58M | 818.22M | 788.73M | 831.93M | 904.48M |
Total Liabilities | 570.18M | 585.95M | 594.21M | 565.25M | 640.16M |
Total Equity | 345.4M | 232.27M | 194.52M | 266.68M | 264.33M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Total Assets | 389.25M | 960.57M | 881.77M | 760.22M | 788.73M |
Total Liabilities | 355.02M | 756.01M | 683.1M | 590.35M | 594.21M |
Total Equity | 34.23M | 204.56M | 198.66M | 169.87M | 194.52M |
Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Operating | -327.78M | -496.86M | -594.74M | -132.98M | -141.32M |
Investing | -631k | -678k | -674k | -293k | -383k |
Financing | 392.67M | 398.41M | 394.5M | 108.21M | 150.7M |
Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
Operating | -211.14M | -160.49M | -563.13M | -513.75M | -594.74M |
Investing | -1.69M | -316.99M | 247.62M | 59.89M | -674k |
Financing | 388.54M | 692.18M | 392.24M | 365.66M | 394.5M |
Market Cap | 3.34B |
Price to Earnings Ratio | -6.39 |
Price to Sales Ratio | 8.47 |
Price to Cash Ratio | 9.56 |
Price to Book Ratio | 17.26 |
Dividend Yield | - |
Shares Outstanding | 121.77M |
Average Volume (1 week) | 5.52M |
Average Volume (1 Month) | 2.92M |
52 Week Change | -32.00% |
52 Week High | 73.80 |
52 Week Low | 26.75 |
Spread (Intraday) | 0.03 (0.11%) |
Company Name | Apellis Pharmaceuticals Inc |
Address |
108 lakeland ave dover, delaware 19901 |
Website | https://www.apellis.com |
Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions